Werner Scheithauer
About
Werner Scheithauer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Werner Scheithauer has authored 350 papers receiving a total of 18.2k indexed citations (citations by other indexed papers that have themselves been cited), including 289 papers in Oncology, 132 papers in Pulmonary and Respiratory Medicine and 54 papers in Cancer Research. Recurrent topics in Werner Scheithauer's work include Colorectal Cancer Treatments and Studies (185 papers), Cancer Treatment and Pharmacology (122 papers) and Gastric Cancer Management and Outcomes (64 papers). Werner Scheithauer is often cited by papers focused on Colorectal Cancer Treatments and Studies (185 papers), Cancer Treatment and Pharmacology (122 papers) and Gastric Cancer Management and Outcomes (64 papers). Werner Scheithauer collaborates with scholars based in Austria, Germany and United States. Werner Scheithauer's co-authors include Gabriela Kornek, Arié Figer, Eduardo Díaz‐Rubio, D. Depisch, Markus Raderer, Sheryl Koski, Leonard B. Saltz, Stephen Clarke, Jim Cassidy and Thomas Gruenberger and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.
In The Last Decade
Werner Scheithauer
334 papers receiving 17.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Werner Scheithauer Austria | 57 | 14.5k | 5.4k | 4.6k | 4.1k | 2.3k | 350 | 18.2k | ||
| Christophe Louvet France | 54 | 14.9k 1.0× | 6.1k 1.1× | 3.6k 0.8× | 4.2k 1.0× | 2.5k 1.1× | 278 | 17.8k | ||
| Arié Figer Israel | 35 | 11.6k 0.8× | 4.1k 0.7× | 3.4k 0.7× | 2.6k 0.6× | 2.1k 0.9× | 107 | 14.6k | ||
| Steven R. Alberts United States | 60 | 12.4k 0.9× | 5.2k 1.0× | 3.3k 0.7× | 4.6k 1.1× | 2.3k 1.0× | 311 | 17.1k | ||
| Valérie Boige France | 63 | 9.5k 0.7× | 6.2k 1.1× | 3.9k 0.9× | 5.7k 1.4× | 1.9k 0.8× | 287 | 17.6k | ||
| Philippe Rougier France | 52 | 17.4k 1.2× | 7.4k 1.4× | 6.6k 1.4× | 5.0k 1.2× | 2.7k 1.1× | 128 | 22.4k | ||
| Ian Chau United Kingdom | 56 | 13.1k 0.9× | 7.2k 1.3× | 3.2k 0.7× | 5.4k 1.3× | 2.4k 1.0× | 473 | 18.8k | ||
| Aimery de Gramont France | 64 | 20.1k 1.4× | 6.8k 1.2× | 4.7k 1.0× | 5.3k 1.3× | 2.4k 1.0× | 333 | 25.0k | ||
| Cathy Eng United States | 61 | 10.8k 0.7× | 3.9k 0.7× | 4.2k 0.9× | 6.3k 1.5× | 1.8k 0.8× | 409 | 16.2k | ||
| Alan P. Venook United States | 67 | 9.8k 0.7× | 3.8k 0.7× | 5.2k 1.1× | 3.5k 0.9× | 3.0k 1.3× | 365 | 17.5k | ||
| Bernard Nordlinger France | 63 | 14.9k 1.0× | 5.6k 1.0× | 9.4k 2.1× | 8.0k 1.9× | 1.8k 0.8× | 266 | 21.5k |
Countries citing papers authored by Werner Scheithauer
Since
Specialization
Citations
This map shows the geographic impact of Werner Scheithauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Werner Scheithauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Werner Scheithauer more than expected).
Fields of papers citing papers by Werner Scheithauer
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Werner Scheithauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Werner Scheithauer. The network helps show where Werner Scheithauer may publish in the future.
Co-authorship network of co-authors of Werner Scheithauer
This figure shows the co-authorship network connecting the top 25 collaborators of Werner Scheithauer. A scholar is included among the top collaborators of Werner Scheithauer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Werner Scheithauer. Werner Scheithauer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Stahler, Arndt, Dominik Paul Modest, Sebastian Stintzing, et al.. (2024). Consensus molecular subtypes (CMS) as prognostic and predictive biomarkers of RAS wild-type (WT) metastatic colorectal cancer (mCRC): Pooled analysis of the randomized trials FIRE-1, FIRE-3, XELAVIRI, and PanaMa.. Journal of Clinical Oncology. 42(16_suppl). 3529–3529.
2.
Holch, Julian Walter, Sebastian Stintzing, Kathrin Heinrich, et al.. (2024). Refining first-line treatment decision in RAS wildtype (RAS-WT) metastatic colorectal cancer (mCRC) by combining clinical biomarkers: Results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).. Journal of Clinical Oncology. 42(3_suppl). 13–13.
3.
Tabernero, Josep, et al.. (2017). nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial. SHILAP Revista de lepidopterología.
4.
Thaler, J., Cihan Ay, Nigel Mackman, et al.. (2012). Microparticle‐associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. Journal of Thrombosis and Haemostasis. 10(7). 1363–1370.
5.
Saltz, Leonard B., Stephen Clarke, Eduardo Díaz‐Rubio, et al.. (2008). Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. Journal of Clinical Oncology. 26(12). 2013–2019.
6.
Cutsem, Eric Van, Salvatore Siena, Yves Humblet, et al.. (2007). An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Annals of Oncology. 19(1). 92–98.
7.
Puhalla, Harald, B. Schuell, H. Pokorny, et al.. (2005). Treatment and outcome of intrahepatic cholangiocellular carcinoma. The American Journal of Surgery. 189(2). 173–177.
8.
Twelves, C.J., J McKendrick, Oscar Bertetto, et al.. (2004). Pharmacoeconomic analysis of Capecitabine in the adjuvant setting. Results from the X-ACT trial comparing capecitabine with 5-FU/LV in patients with Dukes' C colon cancer. Annals of Oncology. 15. 73–73.
9.
Wöhrer, Stefan, Johannes Drach, Michael Hejna, et al.. (2003). Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). Annals of Oncology. 14(12). 1758–1761.
10.
Scheithauer, Werner, B. Schüll, H. Ulrich-Pur, et al.. (2002). Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Annals of Oncology. 14(1). 97–104.
11.
Scheithauer, Werner, Gabriela Kornek, Markus Raderer, et al.. (1999). Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma. British Journal of Cancer. 80(11). 1797–1802.
12.
Stöger, Herbert, H. Samonigg, Michael Krainer, et al.. (1998). Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor. European Journal of Cancer. 34(4). 482–488.
13.
Scheithauer, Werner, A Marczell, J. Karner, et al.. (1998). Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma. British Journal of Cancer. 77(8). 1349–1354.
14.
Kornek, Gabriela, Thomas Schenk, Heinz Ludwig, Michael Hejna, & Werner Scheithauer. (1996). Placebo-Controlled Trial of Medroxy – progesterone Acetate in Gastrointestinal Malignancies and Cachexia. Oncology Research and Treatment. 19(2). 164–168.
15.
Raderer, Markus, Thomas Maca, Johannes Kästner, et al.. (1995). Tolerance of the Novel Chemosensitizer Dexverapamil in Combination with Anthracycline Chemotherapy: a Prospective Toxicity Analysis in Advanced Gastrointestinal Cancer. Oncology Research and Treatment. 18(5). 462–467.
16.
Scheithauer, Werner, D. Depisch, Gabriela Kornek, et al.. (1994). Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer. Cancer. 73(6). 1562–1568.
17.
Raderer, Markus, et al.. (1993). A Phase l/ll Study of Quinidine, a Potential Multidrug Resistance-Reversing Agent, in Combination with Pirarubicin in Patients with Advanced Refractory Breast Cancer. Oncology Research and Treatment. 16(6). 450–453.
18.
Scheithauer, Werner, et al.. (1987). VAD protocol for treatment of advanced refractory multiple myeloma. Annals of Hematology. 55(3). 145–152.
19.
Ludwig, Heinz, Agostino Cortelezzi, E Polli, et al.. (1985). Treatment with Recombinant Interferon-Alpha-2C: Multiple Myeloma and Thrombocythaemia in Myeloproliferative Diseases. Oncology. 42(1). 19–25.
20.
Janssen, J, Heinz Ludwig, Werner Scheithauer, et al.. (1985). Phase I Study of Recombinant Human Interferon Alpha-2C in Patients with Chemotherapy-Refractory Malignancies. Oncology. 42(1). 3–6.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Christophe Louvet Breakdown of academic impact, for papers by Arié Figer Breakdown of academic impact, for papers by Steven R. Alberts Breakdown of academic impact, for papers by Valérie Boige Breakdown of academic impact, for papers by Philippe Rougier Breakdown of academic impact, for papers by Ian Chau Breakdown of academic impact, for papers by Aimery de Gramont Breakdown of academic impact, for papers by Cathy Eng Breakdown of academic impact, for papers by Alan P. Venook Breakdown of academic impact, for papers by Bernard Nordlinger